After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...